ST Huluwa announced that on July 29, 2026, after review and approval by the shareholders' meeting, the company terminated the two R&D projects of levosalbutamol hydrochloride, ipratropium bromide atomized inhalation solution and afoterol tartrate atomized inhalation solution. The total capital was adjusted to 1.04 million yuan for other sub-projects of the “Drug Research and Development Project”. On the same day, the company signed an agreement with the relevant parties to transfer 100% of the property rights of the L-salbutamol and ipratropium bromide atomized inhalation solution research project to Beijing Yingkerui Innovative Pharmaceutical Research Co., Ltd. for 17.6 million yuan. The payment was made in three installments. This transaction is beneficial to return capital, avoid risks, and does not affect the normal operation of the company.

ST Huluwa announced that on July 29, 2026, after review and approval by the shareholders' meeting, the company terminated the two R&D projects of levosalbutamol hydrochloride, ipratropium bromide atomized inhalation solution and afoterol tartrate atomized inhalation solution. The total capital was adjusted to 1.04 million yuan for other sub-projects of the “Drug Research and Development Project”. On the same day, the company signed an agreement with the relevant parties to transfer 100% of the property rights of the L-salbutamol and ipratropium bromide atomized inhalation solution research project to Beijing Yingkerui Innovative Pharmaceutical Research Co., Ltd. for 17.6 million yuan. The payment was made in three installments. This transaction is beneficial to return capital, avoid risks, and does not affect the normal operation of the company.